Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эффективность и безопасность современных мочегонных препаратов у пациентов с артериальной гипертонией осложненного течения - Журнал Системные Гипертензии №1 (2005)
Эффективность и безопасность современных мочегонных препаратов у пациентов с артериальной гипертонией осложненного течения
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Neaton JD, Grimm RH, Prineas RJ et al. Treatment of mild hypertension study. JAMA 1993; 270: 713–24.
2. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high – risk hypertensive patients randomized to angiotensin – converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–97.
3. SHEP cooperative research group. Prevention of stroke by antihypertesive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.
4. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP – Hypertension). Lancet 1991; 338: 1281–5.
5. Medical research counsil working party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104.
6. Medical research counsil working party. Medical research counsil trial to treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12.
7. Леонова М.В., Белоусов Д.Ю., аналитическая группа исследования ПИФАГОР. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии. Качествен. клин. практика. 2002; 3: 47–53.
8. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double – blind treatment with a long – acting calcium – channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Lancet 2000; 356: 366–72.
9. Hansson L. Sustained release formulations in hypertension: pharmacokinetic innovations with indapamide SR 1.5 mg and related clinical implications. Clin Pharm 1999; 37: 1–38.
10. Ambrosioni E, Safar M, Degaute J-P et al. Low – dose antihypertesive therapy with 1.5 mg sustained release indapamide: results of randomized double – blind controlled studies. J Hypertension 1998; 16: 1677–84.
11. Donnely R. Clinical implications of indapamide sustained release 1,5 mg in hypertension. Clin Pharmacokinetics 1999; 37 (Suppl. 1): 21–32.
12. Emerian J-P, Knauf H, Puja Las JO. A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlirothiazide 25 mg in eldery hypertensive patients: a randomized double – blind controlled study. J Hypertension 2001; 19: 343–50.
13. Cooper RS, Simmons BE, Castaner A et al. Left ventricular hypertrophy is associated with worse survival in independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65: 441–5.
14. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertension 2000; 18: 1465–75.
15. Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertension 2004; 22: 1613–22.
16. Weidmann P. Metabolic profile of indapamide sustained – release in patients with hypertension. Drug safety 2001; 24: 1155–65.
2. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high – risk hypertensive patients randomized to angiotensin – converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–97.
3. SHEP cooperative research group. Prevention of stroke by antihypertesive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.
4. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP – Hypertension). Lancet 1991; 338: 1281–5.
5. Medical research counsil working party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104.
6. Medical research counsil working party. Medical research counsil trial to treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12.
7. Леонова М.В., Белоусов Д.Ю., аналитическая группа исследования ПИФАГОР. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии. Качествен. клин. практика. 2002; 3: 47–53.
8. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double – blind treatment with a long – acting calcium – channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Lancet 2000; 356: 366–72.
9. Hansson L. Sustained release formulations in hypertension: pharmacokinetic innovations with indapamide SR 1.5 mg and related clinical implications. Clin Pharm 1999; 37: 1–38.
10. Ambrosioni E, Safar M, Degaute J-P et al. Low – dose antihypertesive therapy with 1.5 mg sustained release indapamide: results of randomized double – blind controlled studies. J Hypertension 1998; 16: 1677–84.
11. Donnely R. Clinical implications of indapamide sustained release 1,5 mg in hypertension. Clin Pharmacokinetics 1999; 37 (Suppl. 1): 21–32.
12. Emerian J-P, Knauf H, Puja Las JO. A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlirothiazide 25 mg in eldery hypertensive patients: a randomized double – blind controlled study. J Hypertension 2001; 19: 343–50.
13. Cooper RS, Simmons BE, Castaner A et al. Left ventricular hypertrophy is associated with worse survival in independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65: 441–5.
14. Gosse P, Sheridan DJ, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertension 2000; 18: 1465–75.
15. Marre M, Puig JG, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertension 2004; 22: 1613–22.
16. Weidmann P. Metabolic profile of indapamide sustained – release in patients with hypertension. Drug safety 2001; 24: 1155–65.
Авторы
И.Е.Чазова
РКНПК МЗ и СР РФ, Москва
РКНПК МЗ и СР РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.